JAZZ - Jazz cannabis spray for multiple sclerosis fails phase 3 trial

Jazz Pharmaceuticals (NASDAQ:JAZZ) said its cannabis-based nabiximols oromucosal spray (JZP378) failed to meet the main goal of a late-stage study in patients with multiple sclerosis (MS) spasticity. MS is a potentially disabling disease affecting the central nervous system (brain and spinal cord). Spasticity is a common symptom of MS and is characterized by tightness or stiffness of the muscles, generally in the legs. Jazz said in a June 28 release that the phase 3 trial, dubbed RELEASE MSS1 trial did not meet the main goal of change in Lower Limb Muscle Tone-6 (LLMT-6) from the time treatment started to day 21. The study enrolled 68 adults. Jazz inherited nabiximols, which is sold as Sativex outside the U.S., via a $7.2B acquisition of GW Pharmaceuticals. Sativex, which is formulated from extracts of the cannabis sativa plant and contains tetrahydrocannabinol (THC) and cannabidiol (CBD), is used to treat adult patients with moderate to severe spasticity due to MS who

For further details see:

Jazz cannabis spray for multiple sclerosis fails phase 3 trial